Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Olatorepatide AI and MDV Pens in Overweight/Obese Adults
NCT07057674Phase 1Recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Apr 2025
- Primary completion
- Feb 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of olatorepatide in obesity and Overweight (2 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoint: Bioequivalence of HS-20094 MDV pen and AI pen following multiple doses at 15 mg. Started Apr 2025; status: recruiting.
02
Drugs
olatorepatide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT07057674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07057674.